Research · Sep 3, 2026
[STE] STERIS Thesis 2026: Cantel Integration Tests Sterilization Services Cycle
STERIS plc (NYSE: STE; Irish-domiciled holding company structure post-2018 Synergy Health merger) FY2025 (fiscal year ending March 2026) revenue ~$5.4-5.6B (+5-8%) with adj. EPS ~$8.50-10.00 reflecting continued post-2024 surgical procedure recovery + selected Healthcare segment leadership ($3.8B; ~50%+ US hospital sterilization market share) + selected April 2021 Cantel Medical $4.6B integration realization + selected ~20-year continuous dividend track + selected operational excellence under CEO Daniel Carestio (~3-year tenure since June 2022). Leading global infection prevention + sterilization products + services firm. Founded 1985 in Mentor Ohio (~40-year heritage; selected initial focus on selected sterilization technology); current STERIS plc structure formed via 2018 Synergy Health merger creating Irish-domiciled holding company. Headquartered in Dublin Ireland (operational HQ Mentor Ohio); ~17,000+ employees globally with ~$5.4-5.6B revenue. Three reporting segments: Healthcare ~70% revenue ($3.8B — surgical instrument cleaning + sterilization + infection prevention products + services for hospitals; ~50%+ US hospital sterilization market share + dominant capital equipment + sterilizers + washers + post-Cantel endoscopy reprocessing; capital equipment ~$700M+ + consumables ~$1.2B+ + service contracts ~$800M-1B + endoscopy reprocessing ~$500M+), Applied Sterilization Technologies ~20% ($1.0B — contract sterilization for medical device manufacturers + biopharma; gamma + ethylene oxide + E-beam sterilization), Life Sciences ~10% ($0.5B — sterilization for biopharma + pharmaceutical manufacturing). April 2021 Cantel Medical $4.6B all-cash + stock acquisition: transformative deal contributed ~$1.1B revenue + ~3,500 employees + medical device sterilization + endoscopy reprocessing expansion; ~$300-400M+ annualized cost synergies achieved by FY2024; selected post-2021 Cantel integration into Healthcare segment + medical device manufacturer sterilization customers expanded. CEO Daniel Carestio since June 2022 (succeeded Walt Rosebrough CEO 2007-June 2022 retired who led 2007-2022 strategic transformation including 2018 Synergy Health merger + 2021 Cantel Medical $4.6B; Carestio ex-STERIS COO 2019-2022 + ex-various STERIS roles + ~25-year career). Selected internal succession reflected board's preference for operational continuity through Cantel integration. Capital return: ~$2.20-2.40 annual dividend FY2025 (~$0.55-0.60/quarter; ~20+ consecutive year continuous increases); modest buybacks $200-400M FY2025; investment-grade Baa1/BBB+ credit ratings; FCF $700M-900M. FY2026 thesis: Healthcare cycle recovery + Cantel integration realization + AST cycle recovery + ~21-year dividend track. Risks: major Cantel goodwill impairment, hospital capex pause, medical device manufacturing cycle reversal, currency translation severe.